Studies suggest that GLP-1 receptor agonists may improve cardiovascular outcomes, reduce inflammation and enhance metabolic health
Additionally, the magnitude of peripheral metabolic effects, like insulin secretion, glucagon suppression, and modulation of gut hormones, can also be influenced by a patients existing metabolic status and degree of insulin resistance [29,30]
Weight-loss trials can measure body weight, metabolic markers, adverse events, and defined clinical endpoints
These tests, conducted in a separate cohort, were designed to assess generalizability across related incretin-based compounds and may inform the clinical use and continued development of GLP-1-based therapies for AUD, while also serving as a foundation for future studies evaluating compound- and receptor-specific mechanisms
The Act was amended to include a much higher standard: drugmakers now needed to conduct controlled trials in order to demonstrate that their products were effective
